New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Acumen Pharmaceuticals, Inc. (ABOS) vs Seres Therapeutics, Inc. (MCRB)

Acumen Pharmaceuticals, Inc. and Seres Therapeutics, Inc. are both Biotechnology companies. Acumen Pharmaceuticals, Inc. and Seres Therapeutics, Inc. are of similar size ($14.0M and $13.6M). Acumen Pharmaceuticals, Inc. has the higher net margin (−510.1% vs −2,209.6%) and the higher return on invested capital (0.00% vs −1,267.8%). Across the 14 metrics below, Seres Therapeutics, Inc. leads on 8 and Acumen Pharmaceuticals, Inc. on 6.

Valuation

Metric ABOS MCRB Biotechnology median
P/E n/m n/m 8.49
P/S 9.07 5.87 8.56
P/B 0.38 0.58 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.38 0.07 0.69
EV/Sales (27.38) (2.38) 8.00
Earnings yield (855.56%) (400.00%) (35.81%)
Free cash flow yield (675.63%) (510.53%) (25.41%)

Profitability

Metric ABOS MCRB Biotechnology median
Gross margin 100.00% 100.00% 70.18%
Operating margin (550.97%) (3,656.89%) 0.00%
Net margin (510.10%) (2,209.55%) 0.00%
Free cash flow margin (518.80%) — 0.00%
Return on equity (162.72%) (144.35%) (51.58%)
Return on assets (91.28%) (44.85%) (45.91%)
Return on invested capital 0.00% (1,267.77%) 0.00%

Growth

Metric ABOS MCRB Biotechnology median
Revenue growth (TTM) — — 7.20%
EPS growth (last fiscal year) (16.96%) — 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric ABOS MCRB Biotechnology median
Debt to equity 0.76 0.00 0.00
Current ratio 1.89 1.65 4.79
Net debt to EBITDA 0.69 0.51 1.01

Dividend

Metric ABOS MCRB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ABOS MCRB Biotechnology median
Market cap 13.98m 13.56m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack